Assessing how genetic variation affects GLP-1 receptor pharmacology
Assessing how genetic variation affects GLP-1 receptor pharmacology
GLP-1 receptor agonists (GLP-1R agonists or GLP-1RAs) are a class of drugs that mimic the human GLP-1 hormone to manage type 2 diabetes and obesity, that are being taken by millions of Americans. However, not all people respond to GLP-1RAs. One explanation is genetic variation in GLP-1R. Over 500 genetic variants of GLP-1R have been described in the human population. This project aims to characterize how these variant GLP-1R proteins vary in their sensitivity to GLP-1RAs.
Some GLP-1RA drugs are based on a naturally occurring component of Gila monster venom, exendin-4. Gila monsters have two other homologs of GLP-1. Evidence suggests that exendin-4 may have evolved as a defensive peptide in Gila monsters against predators (largely mammals). The specificity and longevity of the Gila monster exendin-4 against the variation that exists across vertebrate species is still an open question, and will also be characterized in this project.

